Variant HSP70 Peptides Modulate Dendritic Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like vitiligo are limited and largely unsuccessful, with existing methods failing to effectively address the autoimmune response that leads to depigmentation.
Innovation Solution
Administration of variant peptides representing a sequence of amino acids found in heat shock protein 70 (HSP70) to reduce the activation of dendritic cells, thereby mitigating the autoimmune response and its symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatment methods are used for vitiligo, then treatment options are available, but they are largely unsuccessful in addressing the autoimmune response
Solution Approach 1:
The patent uses HSP70 peptides as intermediary molecules that bind to dendritic cells and modulate their function. These peptides act as mediators between the immune system and melanocytes, suppressing the autoimmune response without directly attacking the underlying immune dysfunction. The HSP70 peptides serve as a bridge that translates immune suppression into clinical benefit by reducing dendritic cell activation and subsequent T cell responses against melanocytes.
Solution Approach 2:
The invention changes the biochemical parameters of the immune response by introducing variant HSP70 peptides with specific amino acid sequences that have different binding affinities to dendritic cell receptors. By modifying peptide sequences (e.g., changing residue 396 from arginine to lysine), the treatment alters the activation threshold and intensity of dendritic cells, thereby controlling the autoimmune response intensity to achieve therapeutic effect.
2Reliability
If stress factors trigger autoimmune response in vitiligo, then the autoimmune response is activated, but this leads to depigmentation and disease progression
Solution Approach 1:
The treatment applies preliminary anti-action by administering HSP70 peptides before stress factors can fully activate the harmful autoimmune response. The peptides pre-condition the dendritic cells to resist activation by stress-induced signals, creating a protective barrier against upcoming stressors. This preventive approach counteracts the triggering effect of stress before it leads to melanocyte destruction and depigmentation.
Solution Approach 2:
The invention converts the harmful effect of stress-induced HSP70 release into a beneficial therapeutic effect. Instead of allowing stress-triggered HSP70 to activate dendritic cells and promote autoimmunity, the treatment provides exogenous HSP70 peptides that bind to dendritic cells in a way that suppresses their activating function. The same stress-induced molecular pathway is harnessed to deliver therapeutic suppression of the autoimmune response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of variant HSP70 peptides effectively reduces the activation of dendritic cells, leading to a decrease in autoimmune disease symptoms such as depigmentation, providing a potential therapeutic approach for vitiligo and other autoimmune disorders.
Implementation Method 1
HSP70i is among cytoplasmic chaperones upregulated in response to temperature changes and other forms of stress. Extracellular HSP70i in turn serves as an alarm signal to the immune system by supporting uptake, processing and presentation of chaperoned antigens in the context of MHC class I and II
Data Source
AI summary
Methods of treating autoimmune diseases, such as vitiligo, by using compositions comprising DNA encoding a variant inducible heat shock protein 70 (HSP70i) having a mutation in the dendritic cell binding region thereof (HSP70i435-447) or an isolated variant gene product in the form of HSP70i with a modification in the dendritic cell activating region thereof (HSP70i435-447).